Chemomab Therapeutics
CMMB
12 hedge funds and large institutions have $58.7M invested in Chemomab Therapeutics in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
20% more funds holding
Funds holding: 10 → 12 (+2)
0.01% more ownership
Funds ownership: 0.34% → 0.35% (+0.01%)
29% less capital invested
Capital invested by funds: $82.6M → $58.7M (-$23.9M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$7.1M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.55M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$1.08M |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$790K |
| 5 |
VF
Virtu Financial
New York
|
+$322K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$3.63M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.69M |
| 3 |
Renaissance Technologies
New York
|
-$202K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$172K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$17K |
CMMB Hedge Fund Activity: Q2 2021 in Review
12 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q2 2021, worth a combined $58.7M — down 29% from $82.6M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CMMB positions and 4 closed out — a net gain of 2 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $7.1M. The largest seller was Maven Securities, exiting entirely with an estimated $3.63M sold.
- 12 institutional investors held Chemomab Therapeutics (CMMB) as of Q2 2021, up from 10 in Q1 2021.
- Funds reported $58.7M of Chemomab Therapeutics stock for Q2 2021, down 29% quarter-over-quarter.
- 6 funds opened new Chemomab Therapeutics positions in Q2 2021 and 4 closed out, a net change of +2 holders.
- The largest Chemomab Therapeutics buyer in Q2 2021 was Ikarian Capital, an estimated $7.1M added.
- The largest Chemomab Therapeutics seller in Q2 2021 was Maven Securities, an estimated $3.63M sold.
Based on aggregated 13F filings for Q2 2021.